Kraig Biocraft Laboratories Successfully Completes March/April Production Cycle; May Production Now Underway
Rhea-AI Summary
Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology company specializing in spider silk technology, has announced the successful completion of its March/April spider silk production cycle and the commencement of its May production run. The company reports meeting internal performance benchmarks and production targets, demonstrating progress in its 2025 production scale-up plan.
The achievement builds upon operational and technical advancements from 2024, with production activities in both Vietnam and the U.S. showing consistent execution. This progress supports Kraig Labs' strategy to transition from pilot-scale to commercial-scale production of recombinant spider silk for multiple markets.
Positive
- Production targets and internal performance benchmarks were met for March/April cycle
- Company remains on track to meet full-year production capacity goals
- Successfully expanding manufacturing capabilities across Vietnam and U.S. operations
Negative
- None.
News Market Reaction – KBLB
On the day this news was published, KBLB declined 2.17%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Company Continues to Meet 2025 Scale-Up Targets
ANN ARBOR, Mich., May 06, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it has successfully completed its March/April spider silk production run and is currently well underway with its May production cycle.
This steady progress reflects the Company's continued execution against its 2025 production scale-up plan, which builds on the significant operational and technical advancements achieved throughout 2024. Spider silk production for March and April met internal performance benchmarks and production targets, reinforcing confidence in the expanded capacity and workflow improvements implemented earlier this year.
With May's production already in progress, Kraig Labs is maintaining its momentum and remains on track to meet its full-year production capacity goals. These efforts support Kraig Labs' broader strategy to transition recombinant spider silk from pilot-scale production to commercial viability across multiple markets.
"Our teams in Vietnam and the U.S. continue to demonstrate consistent execution and focus," said Company Founder and CEO, Kim Thompson. "With each completed cycle, we are strengthening our manufacturing capabilities and moving closer to our goal of delivering commercial volumes of eco-friendly, performance fiber."
The Company will provide further updates as it progresses through its 2025 production calendar.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/470ab210-4578-4921-bb49-d7cd57ea36ba
FAQ
What did Kraig Biocraft Laboratories (KBLB) announce about its production cycles in May 2025?
Where does Kraig Biocraft Laboratories (KBLB) conduct its spider silk production operations?
What are Kraig Biocraft Laboratories' (KBLB) production goals for 2025?
Who is the CEO of Kraig Biocraft Laboratories (KBLB)?
